Market Signal Briefing

53.77K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CNQ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

March 06, 2026 07:00 ET  | Source: Nano Labs Ltd.

HONG KONG, March 06, 2026 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (the “Company,” “we,” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, today announced the official launch of iPollo ClawPC A1 Mini, a new product under its sub-brand iPollo.

This product is a dedicated hardware solution designed to efficiently and conveniently support the OpenClaw AI Agent System. Engineered to address diverse usage scenarios, including gaming, professional content creation, and smart office environments, it delivers an efficient, fluent, and localized AI-powered intelligent experience for users.

OpenClaw is an open-source autonomous AI agent platform designed to build intelligent assistants capable of reasoning, retaining memory, and executing tasks across digital systems. It is an autonomous agent that can execute tasks via large language models, using messaging platforms as the main user interface.

Following its development roadmap, Nano Labs plans to subsequently launch iPollo Claw OS, along with a dedicated Skill Hub tailored for the OpenClaw ecosystem. The Company also intends to introduce additional OpenClaw-compatible hardware products through the iPollo Store (ipollo.com). This product lineup aims to establish an integrated ecosystem spanning terminals and operating systems, as well as both hardware and software.

Mr. Jianping Kong, Chairman and CEO of Nano Labs, commented: “The launch of iPollo ClawPC A1 Mini represents not only an evolution in AI software and hardware integration but also a meaningful step forward in our vision for the emerging Web 4.0 Era. We aim to elevate AI from a supportive tool to an independent and collaborative digital entity. This innovation underscores our commitment to driving technological transformation across the broader industry.”

About Nano Labs Ltd
Nano Labs Ltd is a leading Web 3.0 infrastructure and product solution provider. Nano Labs is committed to the development of high throughput computing (“HTC”) chips and high-performance computing (“HPC”) chips. Nano Labs has built a comprehensive flow processing unit (“FPU”) architecture which offers solution that integrates the features of both HTC and HPC. In addition, Nano Labs has actively positioned itself in the crypto assets space, adopting BNB as its primary reserve asset. It has reserved in mainstream cryptocurrencies including BNB and BTC, and established an integrated platform covering multiple business verticals, including HTC solutions and HPC solutions*. For more information, please visit the Company’s website at: ir.nano.cn.
*According to an industry report prepared by Frost & Sullivan.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s plan to appeal the Staff’s determination, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor Contact:

Nano Labs Ltd
Email: [email protected]

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company) announces that Sue Craig has stepped down from the Company’s Board of Directors, effective March 1, 2026.  

“On behalf of the Board and management team, we would like to sincerely thank Sue for her dedication and contributions during her tenure on the Board,” commented CEO Jim Coates. “Sue’s combination of exploration experience and her deep sense of care for the community have played a defining role in guiding Yukon Metals to the current phase of our development cycle, and we wish her success.”

Following Sue Craig’s departure, the Yukon Metals Board now consists of four board members. The Company will evaluate adding additional directors at such time that it is determined to be appropriate.

About Yukon Metals Corp.

Yukon Metals is a well-financed exploration company with a 17-project portfolio covering more than 43,000 hectares. Built on over 30 years of Berdahl family prospecting, the same team behind Snowline Gold Corp.’s district-scale assets, Yukon Metals provides exposure to copper, gold, silver, and critical metals. While advancing high-priority drill targets at the Birch and AZ copper-gold systems and the Star River gold-silver project, the Company is also conducting generative exploration across its broader portfolio to develop the next pipeline of discovery opportunities. Guided by an experienced leadership team with technical, financial, and Yukon expertise, the Company is well positioned to unlock new mineral discoveries across the Yukon territory.

Yukon Metals is committed to fostering sustainable growth and prosperity within Yukon’s local communities, while also enhancing shareholder value. Rooted in a philosophy of inclusiveness and shared prosperity, the Company’s strategy offers both local community members and investors the opportunity to contribute to and benefit from its success.

The Yukon

The Yukon remains one of the world’s last underexplored mineral belts, offering exceptional discovery potential. The Yukon Territory is home to a highly skilled and conscientious local workforce, shaped by generations of exploration experience coupled with a deep respect for the land.

Recent major discoveries with local roots, such as Snowline Gold Corp.’s Rogue Project - Valley Discovery, highlight the Yukon’s potential to generate fresh district-scale mining opportunities.

ON BEHALF OF THE BOARD OF YUKON METALS CORP.

“Jim Coates”

Jim Coates, CEO & Director
Email: [email protected]

For additional information please contact:

Jim Coates
CEO & Director
Yukon Metals Corp.
Email: [email protected]
Phone: 1 (236) 466-9834

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains certain forward-looking information, including information about the Company’s strategic exploration programs, evaluation and addition of new directors to the Board, potential to be realized across the Company’s diversified portfolio of precious and critical metals projects, the Yukon’s potential to generate fresh district-scale mining opportunities, and the Company’s future plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify the forward-looking information. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking information involves significant risks, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from those discussed or implied in the forward-looking information. Such factors include, among other things: risks and uncertainties relating to the Company’s ability to add new directors to the Board at the appropriate time; the ability to realize potential across the Company’s diversified portfolio of precious and critical metals projects; the Yukon not having the potential to generate fresh district-scale mining opportunities; and other risks and uncertainties. See the section entitled “Risk Factors” in the Company’s listing statement dated May 30, 2024, available under the Company’s profile on SEDAR+ at www.sedarplus.ca for additional risk factors. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking information.

Although the forward-looking information contained in this news release is based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with the forward-looking information. The forward-looking information is made as of the date of this news release, and the Company assumes no obligation to update or revise the information to reflect new events or circumstances, except as required by law.

MONTREAL, March 06, 2026 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today that it has completed the manufacturing of the plasma torch system for its client Constellium, one of the world’s largest aluminum transformation and recycling companies. Delivery of the various system components to one of Constellium’s European facilities is underway and will continue over the next five weeks. An engineering team from PyroGenesis will be on-site to receive the shipments and start installation, with commissioning scheduled during Q2 2026.

As previously announced (press release dated August 5, 2025), PyroGenesis signed an industrial implementation contract with Constellium for the sale of plasma torch technology and related peripheral components, for use in a Constellium aluminum remelting furnace, with commissioning targeted for Q1 2026. This followed a previous announcement (press release dated April 10, 2024) detailing a collaboration agreement whereby Constellium stated its intention to use PyroGenesis plasma torches as potential replacement heating sources in Constellium’s aluminum cast houses. This initiative remains exploratory and conducted at demonstrator scale as part of Constellium’s broader research and development activities to explore alternatives to traditional natural gas burners.

With today’s announcement, PyroGenesis confirms that (i) the initial plasma torch system has been completed, (ii) large component delivery via container ship has already begun, and (iii) installation activities will commence as the various components arrive over the next five weeks.

PROJECT HIGHLIGHTS

Purpose: Constellium to explore PyroGenesis’ all-electric plasma torches, among other alternative technologies, to implement cleaner, more sustainable methods for high-temperature industrial heating, reducing carbon emissions and enhancing energy efficiency in aluminum processing.

Scope: installation and commissioning of proprietary plasma technology in an industrial scale demonstrator furnace at Constellium’s casthouse.

Timeline: shipping is underway, installation activities will commence as components arrive in Europe, with commissioning expected during Q2 2026.

Strategic Impact: supports Constellium’s roadmap to reduce GHG emissions.

“Today’s announcement sets the stage for the first use of PyroGenesis’ plasma system in a factory scale aluminum remelting furnace. Constellium’s aluminum research centre performs some of the most sophisticated large-scale research and testing for their industrial clients in highly demanding sectors such as aerospace and defense. The metal produced from this project is expected to be incorporated into these clients’ commercial applications,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “The transition toward electrified industrial processes must be grounded in both performance and economic viability. This is a balance that our plasma torch technology is uniquely positioned to deliver. By proactively pursuing cleaner and more efficient energy solutions, Constellium is setting the tone for the industry. Together, we are advancing the electrification of an energy-demanding area of aluminum manufacturing.”

INDUSTRY AND MARKET CONTEXT

Primary aluminum production is an energy intensive process that is typically produced using electricity; secondary aluminum production, using recycled aluminum, requires 95% less energy to produce. 1According to Pathways to Decarbonization: A North American Aluminum Roadmap, aluminum production emissions must decline by 24% by 2030, 63% by 2040, and 92% by 2050 compared to 2021 levels to meet net-zero targets, highlighting the urgent need for cleaner technologies across both primary production and secondary remelting. 2Aspects of secondary aluminum production that use fossil fuels (natural gas, etc.), such as the remelting of scrap metal, can potentially utilize alternative energy sources such as plasma.Global aluminum demand is projected to rise nearly 40% by 2030 and up to 80% by 2050, driven by growth in automotive, aerospace, and packaging. 3 4Plasma-based electrification offers a cleaner, scalable alternative to traditional fuel-based heating, aligning with industrial energy transition and decarbonization mandates.

Image: reverberatory melting furnace in use at one of Constellium’s aluminum facilities.
Photo courtesy of Constellium.

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

Cautionary and Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under “Risk Factors” in PyroGenesis’ latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis’ profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.

For further information contact [email protected] or visit http://www.pyrogenesis.com

1 https://natural-resources.canada.ca/minerals-mining/mining-data-statistics-analysis/minerals-metals-facts/aluminum-facts

2 https://www.aluminum.org/Decarb

3 https://international-aluminium.org/report-reveals-global-aluminium-demand-to-reach-new-highs-after-covid/

4 https://www.reuters.com/world/china/world-aluminium-industry-must-cut-emissions-by-77-by-2050-iai-2021-03-16

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/744e1243-7415-4a77-92d8-9c94f03725e3

March 06, 2026 07:00 ET  | Source: Sprott Inc.

TORONTO, March 06, 2026 (GLOBE NEWSWIRE) -- Sprott Inc. (“Sprott” or the “Company”) (NYSE/TSX: SII) today announced that the Toronto Stock Exchange (“TSX”) has approved the Company’s notice of intention to make a normal course issuer bid ("NCIB"). Pursuant to the terms of the NCIB, Sprott may purchase its own common shares for cancellation through the facilities of the TSX, Canadian alternate trading systems, the New York Stock Exchange and/or U.S. alternate trading systems, in each case in accordance with the applicable requirements, and as otherwise permitted under applicable securities laws. The maximum number of common shares which may be purchased by Sprott during the NCIB will not exceed 1,289,312 common shares being approximately 5.0% of 25,786,258 (representing the number of issued and outstanding common shares as of February 28, 2026). The average daily trading volume (the “ADTV”) of the common shares on the TSX for the six-month period ended February 28, 2026 was 84,018. Under the rules of the TSX, Sprott is entitled to repurchase during the same trading day on the TSX up to 25% of the ADTV of the common shares, being 21,004 common shares, except where such purchases are made in accordance with the “block purchase” exemption under applicable TSX policy. Sprott will effect purchases at varying times commencing on March 11, 2026 and ending on March 10, 2027.

In addition to providing shareholders liquidity, Sprott believes that the NCIB represents an attractive investment and manner in which to return capital to shareholders.

Under its current NCIB that commenced on March 11, 2025 and will terminate March 10, 2026, Sprott previously sought and received approval from the TSX to repurchase up to 645,333 common shares. Pursuant to its current NCIB, Sprott has purchased an aggregate of common shares through the facilities of the TSX, alternative Canadian trading systems, the NYSE and alternative U.S. trading systems. 11,691 common shares were purchased on the TSX or alternative Canadian trading systems at a weighted-average price of C$60.45 per common share, for total cash consideration of C$706,720.95, and 15,386 common shares were purchased on the NYSE or alternative U.S. trading systems at a weighted-average price of US$64.97 per common share, for total cash consideration of US$999,628.42. Sprott did not repurchase the maximum allowance under the current NCIB due to a combination of market-related factors.

The Company has also entered into an automatic share purchase plan (the “ASPP”) with its designated broker in connection with the NCIB. The ASPP allows for the purchase of common shares under the NCIB at times when Sprott normally would not be active in the market due to applicable regulatory restrictions or internal trading black-out periods. Before the commencement of any particular internal trading black-out period, Sprott may, but is not required to, instruct its designated broker to make purchases of the common shares under the NCIB during the ensuing black-out period in accordance with the terms of the ASPP. Such purchases will be determined by the broker in its sole discretion based on parameters established by the Company prior to commencement of the applicable black-out period in accordance with the terms of the ASPP and applicable TSX rules. Outside of these black-out periods, common shares will be purchasable by Sprott at its discretion under its NCIB. The ASPP will be effective concurrently with the NCIB and constitutes an “automatic securities purchase plan” under applicable Canadian securities laws.

About Sprott

Sprott is a global asset manager focused on precious metals and critical materials investments. We are specialists. We believe our in-depth knowledge, experience and relationships separate us from the generalists. Our investment strategies include Exchange Listed Products, Managed Equities and Private Strategies. Sprott has offices in Toronto, New York, Connecticut and California and the company’s common shares are listed on the New York Stock Exchange and the Toronto Stock Exchange under the symbol (SII). For more information, please visit www.sprott.com.

Forward-Looking Statements

Certain statements in this press release contain forward-looking information and forward-looking statements (collectively referred to herein as the “Forward-Looking Statements”) within the meaning of applicable Canadian and U.S. securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify Forward-Looking Statements. In particular, but without limiting the forgoing, this press release contains Forward-Looking Statements pertaining to methods and quantity of any purchases by the Company of its common shares under the NCIB.

Although the Company believes that the Forward-Looking Statements are reasonable, they are not guarantees of future results, performance or achievements. A number of factors or assumptions have been used to develop the Forward-Looking Statements, including: (i) the impact of increasing competition in each business in which the Company operates will not be material; (ii) quality management will be available; (iii) the effects of regulation and tax laws of governmental agencies will be consistent with the current environment; (iv) the impact of public health outbreaks; and (v) those assumptions disclosed under the heading “Critical Accounting Estimates and Significant Judgments” in the Company’s MD&A for the years ended December 31, 2025 and 2024. Actual results, performance or achievements could vary materially from those expressed or implied by the Forward-Looking Statements should assumptions underlying the Forward-Looking Statements prove incorrect or should one or more risks or other factors materialize, including: (i) difficult market conditions; (ii) poor investment performance; (iii) failure to continue to retain and attract quality staff; (iv) employee errors or misconduct resulting in regulatory sanctions or reputational harm; (v) performance fee fluctuations; (vi) a business segment or another counterparty failing to pay its financial obligation; (vii) failure of the Company to meet its demand for cash or fund obligations as they come due; (viii) changes in the investment management industry; (ix) failure to implement effective information security policies, procedures and capabilities; (x) lack of investment opportunities; (xi) risks related to regulatory compliance; (xii) failure to manage risks appropriately; (xiii) failure to deal appropriately with conflicts of interest; (xiv) competitive pressures; (xv) corporate growth which may be difficult to sustain and may place significant demands on existing administrative, operational and financial resources; (xvi) failure to comply with privacy laws; (xvii) failure to successfully implement succession planning; (xviii) foreign exchange risk relating to the relative value of the U.S. dollar; (xix) litigation risk; (xx) failure to develop effective business resiliency plans; (xxi) failure to obtain or maintain sufficient insurance coverage on favorable economic terms; (xxii) historical financial information being not necessarily indicative of future performance; (xxiii) fluctuations of the market price of common shares of the Company; (xxiv) risks relating to the Company’s investment products; (xxv) risks relating to the Company's proprietary investments; (xxvi) risks relating to the Company's private strategies business; (xxvii) those risks described under the heading “Risk Factors” in the Company’s annual information form dated February 18, 2026; and (xxviii) those risks described under the headings “Managing Financial Risks” and “Managing Non-Financial Risks” in the Company’s MD&A for the years ended December 31, 2025 and 2024. The Forward-Looking Statements speak only as of the date hereof, unless otherwise specifically noted, and the Company does not assume any obligation to publicly update any Forward-Looking Statements, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Investor contact information:

Glen Williams
Managing Partner
Investor and Institutional Client Relations
(416) 943-4394
[email protected]

, /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results.

Business Highlights

CARsgen Pipeline Cash and cash equivalents were around RMB1,123 million as of December 31, 2025. Cash and cash equivalents at the end of 2026 are expected to be not less than RMB1,000 million. The net loss for the year ended December 31, 2025 was RMB103 million, representing a decrease of approximately 87% compared to the year ended December 31, 2024. In light of operational factors such as the changes in operating cash flow, we expect to have adequate cash into the 2030. During 2025, CARsgen has received a total of 218 confirmed orders of zevor-cel from its commercialization partner Huadong Medicine. In December 2025, zevor-cel has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025). The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) and granted Priority Review for satri-cel. The results of satri-cel confirmatory Phase II trial in China have been simultaneously published in The Lancet and at the 2025 ASCO Annual Meeting. Multiple allogeneic CAR-T products are in development, covering treatment areas such as hematologic malignancies, solid tumors, and autoimmune diseases. CARsgen independently developed the lentiviral-based CARvivo™ platform for creating in vivo CAR T-cell products. CARsgen entered into strategic cooperation agreements with a key platform enterprise in Jinshan District, Shanghai to establish an advanced commercial manufacturing base for CAR T-cell products. Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "2025 is a pivotal year for CARsgen Therapeutics. As we enter the phase of substantial value realization in commercialization, zevor-cel has demonstrated an excellent market performance. Meanwhile, satri-cel, the world's first CAR-T candidate for solid tumors that has entered the NDA review process, is expected to be approved in the first half of 2026 and initiate commercialization. With its strong clinical value and broad market potential, it is poised to become the company's next core growth driver. In 2025, the company has shifted its focus to the field of allogeneic CAR-T cell therapies. We believe that off-the-shelf cell therapies capable of large-scale production are crucial for serving a broad patient population and opening a new chapter for the industry. Leveraging our proprietary THANK-uCAR® and THANK-u Plus™ platforms, we are advancing multiple allogeneic CAR-T candidates, with encouraging preliminary clinical data demonstrating promising efficacy and a favorable safety profile. Additionally, we are also advancing in vivo CAR T-cell therapies based on our proprietary CARvivo™ platform. Looking ahead, we will continue to unite our efforts, move forward with determination, and execute our strategic plans with rigorous precision, bringing renewed hope to patients worldwide."

Financial Highlights

CARsgen's revenue was around RMB125.7 million for the year ended December 31, 2025 mainly from zevor-cel, autologous BCMA CAR T-cell product in which the primary revenue of zevor-cel was calculated on the basis of ex-works price, rather than on the basis of end-of-market prices. Our revenue is recognized upon completion of ex-works delivery of products. Due to the inherent time cycle of CAR-T manufacturing, there is a discrepancy between the number of orders obtained from Huadong Medicine and number of ex-works deliveries. CARsgen's gross profit was around RMB80 million for the year ended December 31, 2025. In the commercialization stage, we are demonstrating a strong cost competitive advantage, which is mainly due to self-manufacture for plasmids and vectors with stable output and high yield per batch. Our net loss was around RMB103 million for the year ended December 31, 2025, representing a decrease of around RMB695 million from around RMB798 million for the year ended December 31, 2024.

Cash and cash equivalents were around RMB1,123 million as of December 31, 2025, representing a decrease of around RMB356 million from around RMB1,479 million as of December 31, 2024. The decrease was mainly due to research and development expenses, administrative expenses and investment of capital expenditure. Cash and cash equivalents at the end of 2026 are expected to be not less than RMB1,000 million. In light of operational factors such as the changes in operating cash flow, we expect to have adequate cash into the 2030.

Zevor-cel demonstrates rapids sales growth

Zevorcabtagene autoleucel (zevor-cel, R&D code: CT053) is an autologous fully human CAR T-cell product against B-cell maturation antigen (BCMA) approved by the NMPA of China for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent).

CARsgen entered into a collaboration agreement with Huadong Medicine (000963.SZ) for the commercialization of zevor-cel in mainland China. In terms of commercialization, Huadong Medicine has established a dedicated, professional, and comprehensive commercial team to promote the use of zevor-cel and has been utilizing China's multi-layered insurance system to improve patient accessibility. During 2025, certification and regulatory filings for zevor-cel have been completed in more than 20 provinces or cities and we have received a total of 218 confirmed orders from Huadong Medicine. In December, 2025, zevor-cel was included in China's Commercial Health Insurance Innovative Drug Catalogue (2025). We anticipate that growth of sales revenue of zevor-cel will further accelerate with continuous marketing activities and broader insurance coverage.

The updated long-term follow-up results of Phase I clinical trial of CT053 have been published in Blood Advances. The updated data of Phase II clinical trial, involving 102 patients with a median follow-up of 20 months, were published in Experimental Hematology & Oncology. Zevor-cel demonstrates manageable safety profile while eliciting deep and durable responses in R/R MM patients.

CARsgen entered into a collaboration with Dispatch Bio, to conduct a Phase I trial in China, planned to begin in 2026. The trial will evaluate DISP-11, an investigational therapy leveraging Dispatch's first-in class Flare platform – including DV-10, the company's novel tumor-specific virus – and zevor-cel, in patients suffering from solid tumors.

Satri-cel is about to be commercialized in China

Satricabtagene autoleucel (satri-cel, R&D code: CT041) is an autologous humanized CAR T-cell product against Claudin18.2. In China, satri-cel was granted Breakthrough Therapy Designation (BTD) in March 2025 and Priority Review in May 2025 by the CDE. In June 2025, the CDE of NMPA of China has accepted the NDA for satri-cel for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. Satri-cel is the first CAR T-cell therapy for the treatment of solid tumors that has advanced to NDA stage worldwide. It is expected to be approved and start commercialization in the first half of 2026.

The results of satri-cel confirmatory Phase II trial (NCT04581473) in China have been published in The Lancet and were orally presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Satri-cel demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit with a manageable safety profile, compared to standard therapy.

The research results of the Phase Ib registrational clinical trial of satri-cel for PC adjuvant therapy in China (NCT05911217) has been presented as a poster session at European Society for Medical Oncology (ESMO) Congress in October 2025. The trial represents the world's first proof-of-concept (POC) study exploring CAR T-cell therapy for the adjuvant treatment of solid tumors.

In addition, an investigator-initiated trial (IIT) for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786), and an IIT for satri-cel as a sequential therapy following first-line treatment in patients with advanced G/GEJA (NCT07179484) have been conducted in China.

Multiple allogeneic CAR-T product candidates in development

CARsgen has been advancing differentiated allogeneic CAR T-cell products utilizing the CARsgen's proprietary THANK-uCAR® and THANK-u Plus™ platform. THANK-u Plus™ platform, as an enhanced version of THANK-uCAR®, was developed to address the potential impact of NKG2A expression levels on therapeutic efficacy of the allogeneic CAR T-cells.

CT0596 is a BCMA-targeting allogeneic CAR T-cell product candidate deploying our THANK-u Plus™ technology. The IITs are ongoing in China to evaluate the safety and efficacy of CT0596 for the treatment of R/R MM and PCL. Two IND applications for R/R MM and primary plasma cell leukemia (pPCL) separately were submitted to the NMPA in December 2025 and have been accepted. Phase Ib registration trials in China are planned to be initiated in 2026. Preliminary results of an IIT have been presented at the 67th ASH in December 2025.

CT1190B (KJ-C2219) is an allogeneic CAR T-cell product candidate targeting CD19/CD20 deploying our THANK-u Plus™ technology, for hematologic malignancies and autoimmune diseases. The IITs have been initiated for R/R B-NHL, and for systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), separately. It is expected to obtain IND approval from the NMPA for B-cell malignancies in 2026. Phase Ib registration study is planned to be initiated in 2026 in China.

In addition, multiple products against different targets are currently under development: KJ-C2320 against CD38 for acute myeloid leukemia (AML); KJ-C2526 against NKG2DL for AML, other malignancies and senescence; CT1390B against CLL1 for AML; KJ-C2527 against Claudin18.2 for gastric cancer.

On February 25, 2025, CARsgen has entered into the agreements with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise (Limited Partnership), to jointly invest in UCARsgen Biotech Limited.

In vivo CAR-T product candidates in development

Apart from CAR T-cell products manufactured via in vitro gene editing, CARsgen is also developing in vivo CAR T-cell products. CARsgen's proprietary lentiviral-based CARvivo™ platform demonstrates excellent T cell transduction and targeting specificity. KJ-C2529 is an in vivo CAR T-cell product candidate against CD19/CD20 deploying our CARvivo™ platform for the treatment of B-cell lymphoma. An IIT is expected to be initiated in 2026 for the treatment of R/R B-NHL.

Expand CAR-T commercial manufacturing base

CARsgen is actively preparing for capacity expansion, enhancing the manufacturing capabilities for CAR T-cell therapies that meet international standards to support the commercialization of multiple products and strengthen its global competitiveness. On February 12, 2026, CARsgen, through its indirectly wholly-owned subsidiary CARsgen Diagnostics Co., Ltd., signed strategic cooperation agreements with Shanghai Jingong Enterprise Development Co., Ltd., which is a key platform enterprise in the Bay Area High-Tech Zone of Jinshan District, Shanghai. With a total investment amount not exceeding RMB370 million, CARsgen will establish an advanced commercial manufacturing base for CAR T-cell products in Jinshan District, Shanghai. No significant upfront capital expenditure is required from CARsgen, effectively preserving valuable cash flow for core research and development as well as market expansion. In addition, the repurchase mechanism ensures CARsgen can fully acquire asset control after long-term operation, maintaining production stability and enhancing the flexibility of asset layout.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

For more information, please visit https://www.carsgen.com/ 

SOURCE CARsgen Therapeutics

, /PRNewswire/ -- Cyngn (Nasdaq: CYN) today announced the formal grant of a new U.S. patent, US-12530029-B2, titled "System and Method of Adaptive, Real-Time Vehicle System Identification for Autonomous Driving."This issuance brings Cyngn's intellectual property portfolio to 24 U.S. patents, further solidifying the Company's competitive moat in creating vehicle-agnostic autonomous driving solutions.

Cyngn obtains the formal grant of a new U.S. patent titled "System and Method of Adaptive, Real-Time Vehicle System Identification for Autonomous Driving." The patent protects a system that builds real time, gear-specific vehicle models to generate precise control commands, validates those commands through pre-execution simulation, and adapts continuously as hardware degrades—enabling deployment across diverse vehicle types without platform-specific redesigns. Key technical capabilities are described below.

"As we continue to commercialize our technology, building a robust wall of intellectual property around our core innovations is essential," said Lior Tal, CEO of Cyngn. "This patent represents another important layer in our defensive strategy, securing our rights to fundamental methodologies in vehicle adaptability. Expanding our patent portfolio ensures that we protect the long-term value of our technology stack as we scale."

This patent reflects a broader shift underway in industrial automation: intelligence is becoming the defining asset, not just hardware. As warehouses, factories, and logistics operators look to modernize aging fleets rather than replace them outright, adaptable autonomy platforms may shape the next phase of industry growth. Securing intellectual property around vehicle adaptability positions Cyngn within a structural transition toward software-led industrial transformation.

Key Technical Benefits

The patented technology offers significant operational advantages:

Vehicle-Agnostic Scalability: Translates vehicle-agnostic trajectory commands into vehicle-specific control signals, enabling deployment across diverse vehicle types without platform-specific redesigns. Gear-Specific Precision: Generates a separate model for each gear, producing control commands tuned to the vehicle's current operating state for accurate trajectory tracking. Safety Through Simulation: Simulates movement and validates control commands before execution to catch potential errors. Fleet Intelligence: Synchronizes model updates and aggregates kinematic data across an entire fleet, so each vehicle benefits from collective operating experience. Proactive Maintenance Awareness: Monitors component wear (tires, brakes, shock absorbers) and adjusts models to maintain accurate control as hardware degrades. By securing this intellectual property, Cyngn protects the innovations that allow its technology to be versatile and adaptable, supporting the Company's broader mission to bring automation to industrial fleets regardless of the vehicle type.

About Cyngn

Cyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges facing industrial organizations today, such as labor shortages and costly safety incidents.

Cyngn's DriveMod technology empowers customers to seamlessly bring self-driving technology to their operations without high upfront costs or infrastructure installations. DriveMod is currently available on Motrec MT-160 Tuggers and BYD Forklifts.

The DriveMod Tugger hauls up to 12,000 lbs, travels inside and out, and targets a typical payback period of less than 2 years. The DriveMod Forklift lifts heavy loads that use non-standard pallets and is currently available to select customers.

Investor Contact:
Natalie Russell
CFO
[email protected] 

Media Contact:
Luke Renner
Head of Marketing
[email protected] 

Where to Find Cyngn:

Website: https://cyngn.com X: https://x.com/cyngn LinkedIn: https://www.linkedin.com/company/cyngn YouTube: https://www.youtube.com/@cyngnhq Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in the Company's reports to the Securities and Exchange Commission (SEC), including, without limitation the risk factors discussed in the Company's annual report on Form 10-K/A filed with the SEC on November 14, 2025. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Cyngn undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Cyngn

MCLEAN, Va.--(BUSINESS WIRE)--AIRO Group Holdings, Inc. (Nasdaq: AIRO) (“AIRO” or the “Company”), a global leader in advanced aerospace and defense technologies, today announced that Captain Joe Burns, Chief Executive Officer, Mariya Pylypiv, Chief Financial Officer, and Dr. Chirinjeev Kathuria, Executive Chairman, will present at the 2026 Cantor Global Technology & Industrial Growth Conference in New York City on Wednesday, March 11, 2026 at 9:20 am ET, as well as host investor meetings. A.

A Rheinmetall logo is displayed on a truck during the NATO exercise STEADFAST DART 26 in Bergen, Germany, February 19, 2026. REUTERS/Liesa Johannssen Purchase Licensing Rights, opens new tab

CompaniesDUESSELDORF, March 6 (Reuters) - German defence company Rheinmetall (RHMG.DE), opens new tab said on ​Friday that the war in ‌Iran validates its plans to expand missile production as quickly as ​possible to meet ​rapidly growing demand.

The company sees itself as ideally positioned ⁠to play a key ​role as an industrial partner ​in rockets and components, Rheinmetall told Reuters in response to an inquiry.

The Reuters Iran Briefing newsletter keeps you informed with the latest developments and analysis of the Iran war. Sign up here.

New ​production facilities for missiles ​and rocket engines are planned at ‌its ⁠Unterluess site in Germany, which are expected to be completed in the first ​quarter of ​2027, ⁠as well as in its Spanish site ​of Burgos.

Rheinmetall said ​that ⁠its initiatives are in response to limited production capacities ⁠in ​the Western world.

Reporting ​by Matthias Inverardi, Writing by Miranda ​Murray, Editing by Friederike Heine

Our Standards: The Thomson Reuters Trust Principles., opens new tab

U.S. stock futures fell on Friday following Thursday's negative close. Futures of the major benchmark indices were lower amid the ongoing Iran-US conflict.

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - METALSOURCE MINING INC. (CSE: MSM) (OTCQB: SFRIF) (FSE: E9Z) (the "Company" or "Metalsource") is pleased to announce that, further to its news releases dated February 10, 2026, it has closed the non-brokered private placement for total gross proceeds of $5,999,998.50 (the "Offering").

The Company has allotted and issued 7,999,998 units (the "Units") at a price of $0.75 per Unit. Each unit consists of one common share of the Company (the "Shares") and one-half of one transferable share purchase warrant (each whole, a "Warrant"), with each Warrant entitling the holder to acquire one additional common share at an exercise price of $1.00 for a period of three (3) years from the closing date.

The Units issued pursuant to the Offering are subject to a four-month and one day hold period from the date of issuance under applicable Canadian securities laws. No finder's fees were paid in connection with the Offering.

Eric Sprott, through 2176423 Ontario Ltd., a corporation beneficially owned by him, acquired 1,333,333 Units pursuant to the Offering for total consideration of $1,000,000.

The Company intends to use the proceeds of the Offering to advance exploration at the Silver Hill and Byrd-Pilot projects in North Carolina, and for general working capital.

About Metalsource Mining Inc.

Metalsource Mining Inc. is a Canadian mineral exploration company focused on advancing high-potential mineral assets through modern, systematic exploration and value-driven discovery.

For more information, please refer to SEDAR+ (www.sedarplus.ca), under the Company's profile.

ON BEHALF OF THE BOARD OF DIRECTORS

Joseph Cullen, Chief Executive Officer and Director

Cautionary Note About Forward-Looking Statements
This news release may include forward-looking statements that are subject to risks and uncertainties. By its nature, this information is subject to ‎‎inherent risks and ‎‎uncertainties that may be general or specific and which give rise to the possibility that ‎‎expectations, ‎‎forecasts, predictions, projections, or conclusions will not prove to be accurate, that ‎‎assumptions may not ‎‎be correct, and that objectives, strategic goals and priorities will not be achieved. ‎‎These risks and ‎‎uncertainties include but are not limited those identified and reported in the Company's ‎‎public filings ‎‎under the Company's SEDAR+ profile at www.sedarplus.ca. Although the Company has ‎‎attempted to identify ‎‎important factors that could cause actual actions, events, or results to differ ‎‎materially from those ‎‎described in forward-looking information, there may be other factors that cause ‎‎actions, events or ‎‎results not to be as anticipated, estimated or intended. There can be no assurance that ‎‎such information ‎‎will prove to be accurate as actual results and future events could differ materially from ‎‎those ‎‎anticipated in such statements. The Company disclaims any intention or obligation to update or ‎‎revise any ‎‎forward-looking information, whether as a result of new information, future events or ‎‎otherwise unless ‎‎required by law.‎

Neither the CSE nor the Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286448

Source: Metalsource Mining Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

U.S. equity futures fell as traders neared the close of a week in which war shocked energy markets and raised inflation fears.

The U.S. has issued a waiver allowing India to buy Russian oil. CNBC's Amitoj Singh reports.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

Markets

These Stocks Are Today’s Movers: Marvell, Gap, Costco, Guidewire, Nutex, and More

By George Glover

In this article

MRVL

GAP

COST

GWRE

SPX

Traders working at the New York Stock Exchange. (NYSE)

Stock futures were sliding Friday as investors awaited the U.S. jobs report for February and oil prices spiked.

SINGAPORE--(BUSINESS WIRE)--On 3 March 2026, the Board of Directors of BW LPG Limited (“BW LPG" or the "Company", OSE ticker code: "BWLPG.OL", NYSE ticker code "BWLP) has approved the award of share options to senior management and certain employees of the Company. This is the final annual award of share options under the five-year long-term management share option plan (“LTIP 2022”) which was launched on 1 March 2022. The options are awarded in connection with the publication of the quarterly.

Signage with logo at the Silicon Valley headquarters of semiconductor company Marvell, Santa Clara, California, August 17, 2017. (Photo via Smith Collection/Gado/Getty Images).

Getty Images

MRVL has risen 15% in pre-market trading after increasing its Q1 revenue forecast to $2.4B compared to the $2.28B consensus figure, indicating accelerating growth through FY27. This report changes the narrative to a significant AI-driven turning point. The crucial question is whether the momentum of custom silicon design wins can be maintained at this new, elevated run-rate.

The company surpassed Q4 estimates, but the primary factor is a notable Q1 guidance increase, forecasting $2.4B in revenue against $2.28B consensus. Management now anticipates FY27 revenue nearing $11B, a substantial increase.

The idea that AI hardware expenditures would become concentrated among just a few companies is faltering; Marvell’s custom silicon and optical capabilities demonstrate that it is a vital enabler.The revised FY27 forecast approaching $11B marks a significant upgrade from previous communications, reshaping the company’s growth trajectory from strong to hyper-growth.Management’s projection of 'accelerating’ YoY growth for each quarter in FY27 indicates that the current success is not a peak, but the beginning of a new, steeper growth path.But here is where it gets interesting. You are learning about this 15% movement after it has occurred. The market has already incorporated the news into its pricing. To identify the next winner prior to the headlines, you require predictive signals, not merely notifications. High Quality Portfolio is built on a foundation that includes such signals.

What To Watch NextHas management’s initial full-year revenue guidance historically been conservative or aggressive following major inflection points like this AI cycle?

If guidance has been conservative, the current $11B FY27 objective may still be achievable, suggesting that the stock’s forward estimates and valuation have not yet been fully accounted for. Observe how this stock has responded to past earnings prints and whether guidance has historically been conservative.

MORE FOR YOU

Additionally, a rules-based risk/reward framework is valuable for assessing investment potential and seeing how various analytical perspectives converge for MRVL stock.

MRVL’s earnings history can reveal how this stock has acted after past reports — yet even a consistent pattern offers no assurance for any single quarter. A pre-market increase of this magnitude serves as a sharp reminder that concentrated single-stock exposure can have both positive and negative outcomes. For investors focused on steady compounding rather than responding to individual earnings occurrences, a diversified portfolio strategy inherently buffers this type of volatility.

Portfolios Win When Stock Picks Fall ShortStocks rise and fall — the key lies in remaining invested. A balanced portfolio enables you to navigate market fluctuations, enhancing gains while minimizing single stock risk.

Consistently outperforming the market is challenging, but the Trefis High Quality (HQ) Portfolio makes it seem attainable. By choosing 30 high-conviction stocks, the HQ strategy has historically outperformed the S&P 500, S&P Mid-cap, and Russell 2000. Find out how this curated selection yields superior risk-adjusted returns in our detailed performance factsheet.

March 06, 2026 05:57 ET  | Source: Dimensional Fund Advisors Ltd

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.KEY INFORMATION   (a)Full name of discloser:Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and also on behalf their investment advisory affiliates (“Dimensional”). The Dimensional entities are investment advisors and Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3. (b)Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offereeJust Group PLC (d)If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure05 March 2026 (f)In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”N/A   2.POSITIONS OF THE PERSON MAKING THE DISCLOSURE   If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a)Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)   Class of relevant security:10p ordinary (GB00BCRX1J15)  InterestsShort Positions  Number%Number% (1)Relevant securities owned and/or controlled:23,165,3702.23 %   (2)Cash-settled derivatives:     (3)Stock-settled derivatives (including options) and agreements to purchase/sell:      Total23,165,370 *2.23 %   * Dimensional Fund Advisors LP and/or its affiliates do not have discretion regarding voting decisions in respect of 94,463 shares that are included in the total above.   All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

     (b)Rights to subscribe for new securities (including directors’ and other employee options)   Class of relevant security in relation to which subscription right exists:  Details, including nature of the rights concerned and relevant percentages:    3.DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE   Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.

 (a)Purchases and sales   Class of relevant securityPurchase/saleNumber of securitiesPrice per unit 10p ordinary (GB00BCRX1J15)Sale4,2122.1687 GBP There was a Transfer In of 4,228 shares of 10p ordinary   (b)Cash-settled derivative transactions   Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit         (c)Stock-settled derivative transactions (including options) (i)Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit          (ii)Exercise   Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit         (d)Other dealings (including subscribing for new securities)        Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)        4.OTHER INFORMATION   (a)Indemnity and other dealing arrangements   Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” None   (b)Agreements, arrangements or understandings relating to options or derivatives   Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none” None   (c)Attachments   Is a Supplemental Form 8 (Open Positions) attached?NO   Date of disclosure06 March 2026 Contact nameThomas Hone Telephone number+44 20 3033 3419    Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

MENLO PARK, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Today, Robinhood Ventures Fund I (RVI) announced the pricing of its initial public offering of 12,615,608 common shares of beneficial interest at an initial public offering price of $25.00 per share, bringing the total size of the Fund to $658.4 million (or up to $705.7 million if the underwriter’s option to purchase additional common shares is exercised in full.) The total fund size is calculated before deducting the sales load and offering expenses. All of the shares are being offered by RVI. The shares are expected to begin trading on the New York Stock Exchange (NYSE) on March 6, 2026 under the symbol RVI, and the offering is expected to close on March 9, 2026, subject to the satisfaction of customary closing conditions.

RVI has granted the underwriter a 30-day option to purchase up to an additional 1,892,341 common shares of beneficial interest.

RVI is a closed-end fund that provides retail investors exposure to a concentrated portfolio of private companies. Investors can learn more by reading the registration statement.

Goldman Sachs & Co. LLC is acting as sole bookrunner for the offering.

A registration statement relating to the sale of common shares of beneficial interest of Robinhood Ventures Fund I was declared effective by the Securities and Exchange Commission on March 5, 2026.

This offering is being made only by means of a final prospectus. Copies of the final prospectus related to the offering, when available, may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or by emailing [email protected]; or from RVI by emailing [email protected]. Investors are advised to carefully consider the investment objectives, risks and charges and expenses of RVI before investing. The prospectus, which contains this and other information about RVI, should be read carefully before investing.

This press release is being made pursuant to, and in accordance with, Rule 134 under the Securities Act of 1933, as amended, and shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Disclosures:

An investment in the Fund is speculative and involves a high degree of risk with substantial risk of loss.

Robinhood Ventures is the investment adviser for RVI. Robinhood Ventures is the dba name for Robinhood Ventures DE, LLC. Robinhood Ventures is an SEC-registered investment adviser and a wholly owned subsidiary of Robinhood Markets, Inc.

Forward-Looking Statements

This communication includes “forward looking statements,” including with respect to the completion of RVI’s initial public offering and the expected listing of RVI’s shares on the New York Stock Exchange under the symbol “RVI.” These statements also include statements regarding RVI’s objectives to expand access to private markets and other statements that are not historical facts. You can sometimes identify forward-looking statements through the use of words or phrases such as “will,” “expect,” “anticipated,” “aim,” “intended,” or similar words and expressions of the future. Forward-looking statements involve known and unknown risks, uncertainties and assumptions, including the risks outlined under “Risks” in the preliminary prospectus and elsewhere in RVI’s filings with the SEC, which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement. RVI and Robinhood have no obligation, and do not undertake any obligation, to update or revise any forward-looking statement made in this communication to reflect changes since the date of this communication, except as required by law.

5281214

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/81d291e8-1f90-4ea4-acde-2fc32c943dc3

DALLAS, March 6, 2026 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the "Company"), a leading Bitcoin miner leveraging its global operations to develop an integrated energy and AI compute platform, today published its key operations update February 2026. To support the next stage of Cango's strategic transformation from pure-play Bitcoin mining to global AI and high-performance computing infrastructure, the Company has updated its Bitcoin treasury policy to focus on optimizing liquidity, capital efficiency, and long-term shareholder value.

The Company Also Announces the Details of the Release of Its Upcoming First Quarter 2026 Financial Results 

, /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that its Canna Cabana retail cannabis store located at 1355 London Road in Sarnia, Ontario, will begin selling recreational cannabis products and consumption accessories for adult use on March 9, 2026. This opening brings High Tide's total store count to 220 Canna Cabana locations across Canada and 96 in the province of Ontario.

High Tide Inc., March 6, 2026 (CNW Group/High Tide Inc.) This location marks the Company's first entry into the Sarnia market and represents a strong demographic fit as it expands further into Southwestern Ontario. Strategically positioned in the city's east end along London Road, the site offers excellent visibility within a well-established commercial node directly across Lambton Mall. The store benefits from a highly complementary tenant mix, co-tenanted with nationally recognized retailers in addition to a concentration of big-box retail located directly across the street.

"I am pleased to announce our entry into the Sarnia market as we continue expanding into high-potential communities across Canada where Canna Cabana does not yet have a presence," said Raj Grover, Founder and Chief Executive Officer of High Tide. "Sarnia offers a strong demographic profile for cannabis retail, and we believe our discount club model will resonate well with local consumers seeking value, selection, and a differentiated retail experience."

"While we are proud to have reached 220 stores nationwide, Canada still presents meaningful opportunities for continued organic expansion. Our approach remains disciplined and data-driven, focusing on quality locations and communities where the fundamentals support long-term growth," added Mr. Grover.

WEBCAST LINK FOR HIGH TIDE EARNINGS EVENT

The Company also announces that it will release its financial and operational results for the quarter ended January 31, 2026, after financial markets close on Tuesday, March 17, 2026. High Tide's first fiscal quarter 2026 financial and operational results will be available on SEDAR+, EDGAR, and on the Company's website at https://hightideinc.com/invest. 

Following the release of its first fiscal quarter financial and operational results, High Tide will host a webcast with Raj Grover, Founder and Chief Executive Officer, and Mayank Mahajan, Chief Financial Officer, to discuss the Company's financial results and what the remaining fiscal year holds for High Tide, at 11:30 AM Eastern Time on Wednesday, March 18, 2026.

https://app.webinar.net/XVw7dN1x5Z6

Participants are encouraged to pre-register for the webcast by clicking on the link above prior to the beginning of the live webcast. Three hours after the live webcast, a replay of the webcast will be available at the same link above.

Participants who wish to ask questions during the event may do so through the call-in line, the access information for which is as follows: 

North American Toll Free: 1-888-510-2154
International Toll Free (Germany): 498005889782

ABOUT HIGH TIDE

High Tide, Inc. is the leading community-grown, retail-forward cannabis enterprise engineered to unleash the full value of the world's most powerful plant. Its wholly owned subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. High Tide (HITI) is uniquely-built around the cannabis consumer, with wholly-diversified and fully-integrated operations across all components of cannabis, including:

Retail: Canna Cabana™ is the largest cannabis retail chain in Canada, with 220 domestic locations. The Company's Canadian bricks-and-mortar operations span British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario, holding a growing 12% share of the market. In 2021, Canna Cabana became the first cannabis discount club retailer in the world. The Company also owns and operates multiple global e-commerce platforms offering accessories and hemp-derived CBD products.

Medical Cannabis Distribution: Remexian Pharma GmbH is a leading German pharmaceutical company built for the purpose of importation and wholesale of medical cannabis products at affordable prices. Among all German medical cannabis procurers, Remexian has one of the most diverse reaches across the globe and is licensed to import from 19 countries including Canada.

High Tide consistently moves ahead of the currents, having been named one of Canada's Top Growing Companies by the Globe and Mail's Report on Business in 2025 for the fifth consecutive year and was recognized as a top 50 company by the TSX Venture Exchange (the "TSXV") in 2022, 2024 and 2025. High Tide was also ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023. To discover the full impact of High Tide, visit www.hightideinc.com. For investment performance, don't miss the High Tide profile pages on SEDAR+ and EDGAR.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

CONTACT INFORMATION

Media Inquiries
Carter Brownlee
Communications and Public Affairs Advisor
High Tide Inc.
[email protected]
403-770-3080

Investor Inquiries
Vahan Ajamian
Capital Markets Advisor
High Tide Inc.
[email protected]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain "forward-looking information" and "forward-looking statements within the meaning of applicable securities legislation. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking statements herein include, but are not limited to, statements regarding: the timing of the new locations opening and beginning to sell recreational cannabis products and consumption accessories for adult use; the expected benefits of the store locations; and the level of competition in the area. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed under the heading "Non-Exhaustive List of Risk Factors" in Schedule A to our current annual information form, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at www.sedarplus.ca and www.sec.gov, which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

SOURCE High Tide Inc.

BALTIMORE, March 06, 2026 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for fourth quarter 2025.(1)

Fourth Quarter 2025 Highlights(1)

Total net revenue was $83.4 million in the fourth quarter 2025 (1) Total Billings were $78.9 million in fourth quarter 2025, a year-over-year increase of 42%Net income was $14.0 million in fourth quarter 2025Cash from Operating Activities for fourth quarter 2025 improved $18.2 million compared to fourth quarter 2024. On a year to date basis, CFFO improved by $68.1 million compared to the year ended December 31, 2024.Cash and cash equivalents were $70.1 million as of December 31, 2025, and no debt outstanding.Announced on March 3, 2026 quarterly and special dividend totaling $0.45 per Class A share projecting FY26 dividends of $1.80 per Class A Share. (1)Net Revenue (a GAAP measure) represents Billings that are recognized over the term of the subscription, which can be multiple years. Billings are amounts invoiced to customers in the period and is thus indicative of the current operating environment and demand for our products.   “FY 2025 was our strongest year of Billings growth since going public in 2021, capped off by terrific Q4 results with Billings increasing 42% year over year and 24% higher than last quarter,” said MarketWise CEO Dr. David Eifrig. “This growth in Billings, coupled with ongoing efficiency initiatives, drove solid cash flow for the year with CFFO of over $40M for FY 2025, which was over a $60M improvement compared to FY 2024. With these results, we beat our FY 2025 guidance for both Billings and CFFO, by a substantial margin. I am grateful to our over 400 employees for their dedication in delivering high-quality, trustworthy, investment research and software tools to our over 2 million subscribers.”

“These strong results, coupled with our confidence in our go-forward strategy, led to the Board decision to increase our regular dividend to Class A Shareholders by 25%. With this increase to the dividend, the annualized dividend yield is over 13%, based on current stock prices. We remain committed to being excellent stewards of our owner’s capital through dividends, share buybacks, and prudent investments in the business.”

Eifrig continued, “As I have mentioned before, a bit over a year ago we made the decision to increase the prices we charge on many of our investment research products and software tools. This shift has resulted in higher revenue per user and better overall margins. As a result, paid subscriber totals have become a less meaningful driver given our focus on efficient growth, renewal efforts, and maximizing life-time values. We are continuing to see an overall improvement in our customer mix, where roughly 50% of our paid subscribers have a cumulative lifetime spend of over $1000.”

“At a more strategic and macro level, I have been asked by folks recently regarding how AI might impact our business. In short, we are excited about the opportunities that AI unlocks for us for a couple primary reasons. First, in a world where data, news, and research have been commoditized, our customers look to our analysts and editors more than ever to make sense of the rapidly evolving investing landscape. Over our 25-year history, we have provided trustworthy, independent financial research to millions of self-directed investors. Some of these customers have been with us for decades. Trust earned over time is a competitive advantage. Second, we are incorporating AI functionality into our investing tools and software. We believe these two elements will be an advantage for us in a competitive environment.”

Eifrig concluded, “Last November we provided preliminary Targets for FY 2026 which was Billings of $290M and CFFO of $45M. Things are off to a good start in 2026 with year to date Billings through February tracking around 10% higher than last year. As such, we are increasing our FY 2026 Guidance to be Billings of $300M and CFFO of $50M. I remind investors that the timing of product launches and marketing campaigns can have a significant impact on results and cash balances from one quarter to another. Thus, it is useful to view our business across a few quarters or on a full year basis. I am enthusiastic about the strategy and plans in place to continue our momentum and create value for our shareholders. I look forward to providing updates as things progress.”

Full Year 2025 Highlights(1)

Paid Subscribers were 374 thousand as of December 31, 2025 compared with 506 thousand as of December 31, 2024Total net revenue was $328.1 million for full year 2025 compared with $408.7 million for full year 2024 (1)Total Billings was $271.2 million for full year 2025 compared with $239.1 million for full year 2024Net income was $64.0 million for full year 2025 compared with $93.1 million for full year 2024Cash from Operating Activities (“CFFO”) was $46.0 million for full year 2025 compared with $(22.2) million for full year 2024 Our summary results and selected financial data are as follows:                         (Unaudited, in millions, except per share data or otherwise noted) 4Q 2024 1Q 2025 2Q 2025 3Q 2025 4Q 2025 TTM 4Q 2025Paid Subscribers (in thousands)  506  473  394  379  374 N/MTotal net revenue $97.5 $83.5 $80.0 $81.3 $83.4 $328.1New "Marketing" Billings (1) $37.0 $51.3 $41.6 $48.7 $57.5 $199.1Net "Renewal" Billings (2) $16.0 $18.3 $15.4 $14.1 $17.5 $65.4Other Billings (3) $2.4 $0.8 $1.2 $0.8 $3.9 $6.7Total Billings $55.4 $70.5 $58.2 $63.7 $78.9 $271.2ARPU (in dollars) $394 $419 $474 $566 $670 $670Net income $26.4 $16.8 $15.3 $17.9 $14.0 $64.0CFFO (4) $6.0 $1.7 $17.8 $2.2 $24.2 $46.0Adjusted CFFO $6.0 $1.7 $17.8 $2.2 $24.2 $46.0Free Cash Flow $6.1 $1.5 $17.5 $1.7 $23.7 $44.4             Earnings per share - basic $1.09 $0.43 $0.55 $0.60 $0.79 $2.41Earnings per share - diluted $1.08 $0.41 $0.53 $0.58 $0.76 $2.31             Regular dividends per Class A share (5) $0.20 $0.20 $0.20 $0.20 $0.20 $0.80Special dividends per Class A share (5) $— $0.60 $0.10 $0.20 $0.20 $1.10Total dividends per Class A share (5) $0.20 $0.80 $0.30 $0.40 $0.40 $1.90             Class A Shares (6)  2.0  2.3  2.4  2.5  2.4  2.4Class B Shares (6)  14.0  13.7  13.6  13.6  13.6  13.6Total Shares (6)  16.0  16.1  16.0  16.1  16.1  16.0             (1) Includes billings from all new subscription sales to new and existing subscribers.(2) Includes billings attributable to renewal and maintenance fee payments. Excludes Membership sales.(3) Includes primarily billings from Revenue Share, Advertising, and Conferences.(4) CFFO will fluctuate from quarter to quarter based on inherent variability in our business (2Q and 4Q tend to be higher; 1Q and 3Q, lower). CFFO can also be impacted by timing of product launches, marketing campaigns and discreet working capital items.
(5) Dividends prior to April 2, 2025 have been retroactively adjusted to give effect to the 1-for-20 reverse stock split. Does not include the regular or special dividends totaling $0.40 declared on October 30, 2025. See dividend guidance in the “Full Year 2026 Targets” section below.(6) Excludes Management and Sponsor Earnout Shares. Amount in the TTM 4Q 2025 column is the average of the last four quartersN/M - Not Meaningful                          Net Revenue versus Billings

Net Revenue represents cash received by the Company for the sale of subscriptions which are then recognized as revenue for GAAP purposes over the term of the subscription, or up to 5 years. Cash received by the company is recorded as Deferred Revenue on the Balance Sheet until such amounts are recognized as Net Revenue. Given the deferred nature of revenue recognition, there can be a significant lag between when cash is received by the Company and when revenue is recognized in the Income Statement. To illustrate, Net Revenue recognized in FY 2025 included the significant cash sales from 2021 and 2022. As such, Net Revenue may not be indicative of the current trajectory or operating environment of the Company. In contrast, Billings, represent current period cash sales by the Company which is reflective of the current, real-time operating activity of the Company. The disconnect between Net Revenue and the current trajectory of the Company can be observed in our 2025 results. Specifically, Net Revenue declined 19.7% from FY 2024 to FY 2025 whereas Billings, the actual cash sales of the business, increased 13.4%. We expect a similar dynamic to occur in FY 2026 where Net Revenue will decline while customer sales activity and Billings increase. Beginning in FY 2027, when the significant sales years of 2021 and 2022 are fully recognized as Net Revenue, we expect a more intuitive relationship between Net Revenue and Billings.

Selected Operational and Financial Supplemental Information

We are providing the additional information below to provide further context on results and trends.

Subscriber Composition Trends

As of December 31, 2025, the Company had 2.4 million active free and paid subscribers. Part of the Company’s acquisition strategy is to convert active free subscribers to paid subscribers. As of December 31, 2025, the Company had 374 thousand paid subscribers, which is relatively flat compared to September 30, 2025.

As previously disclosed, the Company’s strategy has pivoted since mid-2024 to focus on higher priced products. Thus, while the paid subscriber count has declined over the last 2-years in absolute terms, the quality and lifetime value of the subscribers have increased.

As illustrated in the chart below, the customer mix has steadily improved with 65% of customers as of December 31, 2025, having a lifetime spend of over $500. In contrast, the majority of customer churn is from the lower value tiers as those cohorts continue to decline as a percent of the total.

This positive mix shift and improvement in customer quality has contributed to the sales growth and margin expansion experienced over the last several quarters.

Billings 

After several quarters of Billings declines, the Company experienced an inflection point in 4Q 2024 with a return to sequential Billings growth. Other than the favorable spike in Billings in 1Q 2025, Billings have continued a steady increase with 4Q 2025 Billings representing more than a 40% year over year increase in the 4th Quarter.

For FY 2025, Billings were $271.2 million compared to $239.1 million for FY 2024.

Further, as illustrated in the chart below, there has been a historical correlation between our Billings and share price. The correlation, however, has decoupled in recent quarters.

We remain focused on driving higher Billings, coupled with margin expansion, which we believe will increase intrinsic value over time.

Cash from Operating Activities

CFFO was $24.2 million for Q4 2025 which was an improvement of $18.2 million compared to Q4 2024. For FY 2025, CFFO was $46.0 million compared to CFFO of ($22.2) million for FY 2024, or an improvement of over $68.1 million.

Based on the nature of our business, and as illustrated in the chart below, CFFO fluctuates from quarter to quarter. Specifically, Q2 and Q4 tend to have higher CFFO while Q1 and Q3 tend to have lower CFFO. The amount of CFFO in any given quarter is impacted by the timing of product launches, marketing campaigns, and discrete working capital items.

Given this variability, we believe it is useful to evaluate CFFO trends over multiple quarters, or a full year.

Balance Sheet and Capital Structure

As of December 31, 2025, the Company holds cash and cash equivalents of $70.1 million, compared to $50.5 million as of September 30, 2025. The $20 million increase in cash balances is due to strong Cash from Operating Activities in the 4th quarter of 2025 which were partially offset by dividends paid in the quarter.

Partnership tax distributions to MarketWise, LLC’s partners, which arise from our corporate structure, totaled $49.8 million for FY 2025.

Tax distribution payments were significant in FY 2025 due to the timing of taxable income which arose from the Billings in prior years.

For FY 2026, we expect these tax distributions to decline significantly to approximately $35 million, or nearly $15 million lower than FY 2025. Similar to the timing of tax distribution payments in FY 2025, we expect FY 2026 tax distributions to be higher in the first half of the year and lower in the second half. As such, due to the timing of tax distribution payments and the higher working capital needs in the first quarter of each year, we expect overall cash balances to decline in the first half of 2026 before increasing in the second half of 2026.

MarketWise Inc.’s Class A common stock trades on the Nasdaq Global Market under the symbol "MKTW." As of December 31, 2025, the Company had 2,445,010 Class A common shares and 13,612,641 Class B common shares issued and outstanding, totaling 16,057,651 Class A and Class B common shares. When determining the market capitalization or equity value of the Company, we believe it is appropriate to include the total of the Class A and Class B common shares. Net Income attributable to noncontrolling interests on the Income Statement is primarily associated with these B shares and is a result of our corporate structure.

As previously announced, the Board of Directors authorized a stock repurchase program of our Class A common stock. Since April 2025, the Company has repurchased 209,726 shares for $3.4 million. The Company suspended repurchases effective October 30, 2025, after receiving the Proposal described below. The program remains authorized and the Company plans to resume repurchases after filing its FY25 annual report.

On October 29, 2025, the Company announced that it had received a proposal from Monument & Cathedral Holdings, LLC (collectively with its affiliates, “M&C”) to acquire all of the outstanding equity interests of the Company and MarketWise, LLC that are not owned by M&C, for cash consideration of $17.25 per share (the “Proposal”), contingent upon the termination of the Company’s tax receivable agreement. On February 17, 2026, M&C withdrew its Proposal after feedback from the Special Committee of the Company’s Board of Directors that its offer price per share undervalued the Company’s stock. The Special Committee of the Company’s Board of Directors carefully evaluated the Proposal, consistent with its fiduciary duties and in consultation with independent legal and financial advisors, with a focus on maximizing value for shareholders.

The Company remains committed to its standalone strategy of driving sustainable growth in high-margin subscription sales, enhancing operational efficiency, and returning capital to shareholders through dividends and share repurchases.

On March 3, 2026, we announced that our Board of Directors declared a regular cash dividend and a special cash dividend to holders of Class A common stock of $0.25 and $0.20 per share, respectively. The quarterly cash dividend of $0.25 per share represents a 25% increase. The regular and special dividend totaling $0.45 per share represents a 13% projected cash dividend yield at current share prices. A comparable distribution of $0.25 per unit has also been approved to holders of MarketWise, LLC units. The dividend and distribution will be paid on March 31, 2026. The Record Date is March 18, 2026.

Note that the special dividends referenced above arise from the previously mentioned tax distribution payments to noncontrolling interests, and represent the proportionate payment to Marketwise, Inc. To the extent the proportionate payment to Marketwise, Inc. exceeds the amounts required for corporate income taxes, any excess may be distributed to Class A shareholders in the form of dividends. Given the mechanical nature of the tax distribution payments, we expect the quarterly special dividends to continue. The amounts, however, may vary.

FY 2026 Targets

Our strategic plans and initiatives are built around bringing high-quality investing ideas and tools to our customers at a dynamic and volatile time for markets. Our focus will continue to be on delivering high-quality products to our customers, in an efficient manner, which we believe will drive both top line growth and margin expansion next year. Further, we intend to continue our disciplined approach to capital allocation with a mix of dividends, share repurchases, and prudent investments in our business.

For FY 2026, our targets are as follows:

Billings of approximately $300 million for FY 2026, which is growth of approximately 10% from FY 2025 Billings.CFFO of approximately $50 million for FY 2026 which is nearly a 10% YoY increase as compared to FY 2025Dividends to the publicly traded Class A shares of $1.80 per share, inclusive of the recently announced 25% increase in the quarterly regular dividend, and a $0.20 per share per quarter special dividend. Again, these forward-looking targets are based on trends and market conditions as they exist currently, and actual results may differ materially. In the case of dividends, amounts are subject to the ongoing approval by our Board of Directors.

About MarketWise

Founded with a mission to level the playing field for self-directed investors, today MarketWise is a leading multi-brand subscription services platform providing premium financial research, software, education, and tools for investors.

With more than 25 years of operating history, MarketWise serves a community of millions of free and paid subscribers. MarketWise’s products are a trusted source for high-value financial research, education, actionable investment ideas, and investment software. MarketWise is a 100% digital, direct-to-customer company offering its research across a variety of platforms including mobile, desktops, and tablets. MarketWise has a proven, agile, and scalable platform and our vision is to become the leading financial solutions platform for self-directed investors.

Key Business Metrics and Non-GAAP Financial Measures

In this release we discuss certain key business metrics, which we believe provide useful information about the Company’s business and the operational factors underlying the Company’s financial performance. We are not aware of any uniform standards for calculating these key metrics, which may hinder comparability with other companies who may calculate similarly titled metrics in a different way.

Billings are defined as amounts invoiced to customers.

Paid Subscribers are defined as the total number of unique subscribers with at least one paid subscription at the end of the period.

Average revenue per user or ARPU is defined as the trailing four quarters of net Billings divided by the average number of quarterly total Paid Subscribers over that period.

In addition to our results determined in accordance with GAAP, we believe that the below non-GAAP financial measures are useful in evaluating operating performance. We use the below non-GAAP financial measures, collectively, to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. This non-GAAP financial information is presented for supplemental informational purposes only and should not be considered a substitute for financial information presented in accordance with GAAP, and may be different from similarly titled non-GAAP measures used by other companies. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures.

Management uses these non-GAAP measures internally to evaluate performance and make operating decisions, and we believe they provide a meaningful perspective to investors when used in conjunction with our GAAP results.

These non-GAAP measures have limitations as analytical tools, and should not be considered in isolation or as substitutes for analysis of other GAAP financial measures, such as cash flow from operations, operating cash flow margin, and net income. Some of the limitations of using these non-GAAP measures are that these metrics may be calculated differently by other companies in our industry.

Adjusted CFFO is defined as cash flow from operations (“CFFO”) plus or minus any non-recurring items.

Adjusted CFFO Margin is defined as Adjusted CFFO as a percentage of Billings.

We believe that Adjusted CFFO and Adjusted CFFO Margin are useful indicators that provide information to management and investors about our ability to generate cash, and for internal planning and forecasting purposes.

We expect Adjusted CFFO and Adjusted CFFO Margin to fluctuate in future periods as we invest in our business to execute our growth strategy. These activities, along with any non-recurring items as described above, may result in fluctuations in Adjusted CFFO and Adjusted CFFO Margin in future periods.

Free Cash Flow is defined as net cash provided by (used in) operating activities less capital expenditures. We define capital expenditures as purchases of property and equipment plus capitalized software development costs. Acquisitions are not included in capital expenditures.

We believe Free Cash Flow is a useful indicator that provides information to management and investors about the cash generated by the business that is available for discretionary purposes, such as dividends and strategic investments.

Non-GAAP Measures

The following table provides a reconciliation of net cash provided by (used in) operating activities to Adjusted CFFO, and net cash provided by operating activities margin as a percentage of total net revenue to Adjusted CFFO Margin, net cash provided by (used in) operating activities to Free Cash Flow, in each case, the most directly comparable financial measure calculated in accordance with generally accepted accounting principles in the United States (“GAAP”):

(In thousands) Fourth Quarter   Year Ended December 31,     2025   2024  % Change  2025   2024  % ChangeNet cash provided by (used in) operating activities $24,214  $5,985  304.6% $45,958  $(22,150) (307.5)%Total net revenue  83,394   97,478  (14.4)%  328,122   408,701  (19.7)%Net cash provided by (used in) operating activities margin  29.0%  6.1%    14.0% (5.4)%               Adjusted CFFO $24,214  $5,985  304.6% $45,958  $(22,150) (307.5)%Billings  78,854   55,355  42.5%  271,195   239,083  13.4%Adjusted CFFO margin  30.7%  10.8%    16.9%  (9.3%)               Net cash provided by (used in) operating activities $24,214  $5,985  304.6% $45,958  $(22,150) (307.5)%Capital expenditures  (529)  107  (594.4)%  (1,567)  (681) 130.1%Free Cash Flow $23,685  $6,092  288.8% $44,391  $(22,831) (294.4)% NM: Not meaningful

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the financial position, business strategy, and the plans and objectives of management for future operations of MarketWise. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “target,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to: our ability to attract new subscribers and to persuade existing subscribers to renew their subscription agreements with us and to purchase additional products and services from us; our ability to adequately market our products and services, and to develop additional products and product offerings; our ability to manage our growth effectively, including through acquisitions; failure to maintain and protect our reputation for trustworthiness and independence; our ability to attract, develop, and retain capable management, editors, and other key personnel; our ability to grow market share in our existing markets or any new markets we may enter; adverse or weakened conditions in the financial sector, global financial markets, and global economy; current macroeconomic events, including heightened inflation, rise in interest rates and the potential for an economic recession; failure to comply with laws and regulations or other regulatory action or investigations, including the Investment Advisers Act of 1940, as amended; our ability to respond to and adapt to changes in technology and consumer behavior; failure to successfully identify and integrate acquisitions, or dispose of assets and businesses; our public securities’ potential liquidity and trading; the impact of the regulatory environment and complexities with compliance related to such environment; our future capital needs; our ability to maintain an effective system of internal control over financial reporting, and to address and remediate existing material weaknesses in our internal control over financial reporting; and other factors beyond our control.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our filings with the U.S. Securities and Exchange Commission (the “SEC”). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. We do not give any assurance that we will achieve our expectations.

Table 1. Income Statement

 Year Ended December 31,  2025  2024  2023 Net revenue$325,708 $405,357 $443,245 Related party revenue 2,414  3,344  4,937 Total net revenue 328,122  408,701  448,182 Operating expenses:     Cost of revenue(1) 44,335  50,663  56,802 Sales and marketing(1) 130,954  160,707  198,592 General and administrative(1) 78,293  90,712  125,176 Research and development 8,814  9,908  8,831 Depreciation and amortization 2,186  2,753  3,821 Impairment losses 380  4,445  2,583 Related party expense 564  525  572 Total operating expenses 265,526  319,713  396,377 Income from operations 62,596  88,988  51,805 Other income (expense), net 1,040  2,085  (611)Interest income, net 2,963  5,288  4,904 Income before income taxes 66,599  96,361  56,098 Income tax expense 2,558  3,253  1,803 Net income 64,041  93,108  54,295 Net income attributable to noncontrolling interests 58,421  86,049  52,513 Net income attributable to MarketWise, Inc.$5,620 $7,059 $1,782       (1) Cost of revenue, sales and marketing, general and administrative, and research and development expenses are exclusive of depreciation and amortization shown as a separate line item 
Table 2. Balance Sheet

(in thousands, except share and per share data)December 31, 2025  December 31, 2024Assets   Current assets:   Cash and cash equivalents$70,140  $97,876 Accounts receivable 5,722   1,876 Prepaid expenses 10,799   10,051 Related party receivables 838   547 Deferred contract acquisition costs 43,388   57,214 Other current assets 814   1,269 Total current assets 131,701   168,833 Property and equipment, net 453   592 Operating lease right-of-use assets 6,684   3,182 Intangible assets, net 3,813   4,673 Goodwill 30,043   30,043 Deferred contract acquisition costs, noncurrent 34,678   42,121 Deferred tax assets 11,007   10,071 Total assets$218,379  $259,515 Liabilities and stockholders’ deficit   Current liabilities:   Trade and other payables$3,868  $4,011 Related party payables 509   338 Accrued expenses 33,221   23,272 Deferred revenue and other contract liabilities 183,798   217,973 Operating lease liabilities 908   1,629 Other current liabilities 11,900   12,985 Total current liabilities 234,204   260,208 Deferred revenue and other contract liabilities, noncurrent 185,754   209,013 Related party TRA liability, noncurrent (Note 12) 4,260   2,669 Other liabilities, noncurrent 2,611   2,811 Operating lease liabilities, noncurrent 5,175   2,738 Total liabilities 432,004   477,439 Commitments and Contingencies —   — Stockholders’ deficit:   Common stock - Class A, par value of $0.0001 per share, 47,500,000 shares authorized;
   2,445,010 and 1,978,013 shares issued and outstanding at December 31, 2025 and
   December 31, 2024, respectively —   — Common stock - Class B, par value of $0.0001 per share, 15,000,000 shares authorized;
   13,612,641 and 13,994,498 shares issued and outstanding at December 31, 2025 and
    December 31, 2024, respectively 1   1 Preferred stock - par value of $0.0001 per share, 100,000,000 shares authorized; 0 shares
   issued and outstanding at December 31, 2025 and December 31, 2024, respectively —   — Additional paid-in capital 101,945   106,691 Accumulated other comprehensive income 36   56 Accumulated deficit (113,664)  (119,284)Total stockholders’ deficit attributable to MarketWise, Inc. (11,682)  (12,536)Noncontrolling interest (201,943)  (205,388)Total stockholders’ deficit (213,625)  (217,924)Total liabilities and stockholders’ deficit$218,379  $259,515         
Table 3. Cash Flows

 Year ended December 31,  2025   2024   2023 Cash flows from operating activities:     Net income$64,041  $93,108  $54,295 Adjustments to reconcile net income to net cash provided by (used in) operating activities:     Depreciation and amortization 2,186   2,753   3,821 Impairment and other charges 380   4,445   2,583 Stock-based compensation 11,106   12,202   23,384 Change in fair value of contingent consideration (1,194)  507   — Change in fair value of derivative liabilities – other —   —   1,779 Deferred taxes 954   2,872   1,803 Unrealized (gains) losses on foreign currency (20)  (18)  23 Other gains (2,250)  —   — Noncash lease expense 3,172   2,053   2,135 (Gain) loss on sale of business —   (2,030)  1,583 Changes in operating assets and liabilities:     Accounts receivable (3,805)  2,652   (488)Related party receivables and payables, net 1,074   2,622   (2,284)Prepaid expenses (748)  (746)  2,420 Other current assets and other assets 455   1,190   1,533 Deferred contract acquisition costs 20,490   63,468   31,329 Trade and other payables (123)  3,470   (200)Accrued expenses 9,949   (31,769)  9,065 Deferred revenue (56,092)  (162,093)  (67,092)Derivative liabilities —   —   (3,060)Operating lease liabilities (3,312)  (1,446)  (1,501)Other current and long-term liabilities (305)  (15,390)  1,300     Net cash provided by (used in) operating activities 45,958   (22,150)  62,428 Cash flows from investing activities:     Cash paid for acquisitions, net of cash acquired —   —   (170)Purchases of property and equipment (391)  (133)  (65)Capitalized software development costs (1,176)  (548)  (1,662)    Net cash used in investing activities (1,567)  (681)  (1,897)Cash flows from financing activities:     Proceeds from issuance of common stock 418   301   678 Shares and restricted stock units withheld to pay taxes (2,360)  (1,368)  (6,032)Repurchases of stock (3,379)  (10,803)  — Dividends paid (4,776)  (1,506)  (5,744)Distributions to members —   —   — Tax distributions to noncontrolling interests (49,838)  (9,564)  (3,353)Other distributions to noncontrolling interests (12,172)  (11,518)  (49,502)    Net cash used in financing activities (72,107)  (34,458)  (63,953)Effect of exchange rate changes on cash (20)  (9)  21 Net decrease in cash, cash equivalents and restricted cash (27,736)  (57,298)  (3,401)Cash, cash equivalents and restricted cash — beginning of period 97,876   155,174   158,575 Cash, cash equivalents and restricted cash — end of period$70,140  $97,876  $155,174  MarketWise Investor Relations Contact

Erik Mickels – Chief Operating and Financial Officer
Email: [email protected]

MarketWise Media Contact

Email: [email protected]

Charts accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/d6d9d457-d14e-46be-8e4c-b35ac5b159c5

https://www.globenewswire.com/NewsRoom/AttachmentNg/9ba9493c-04ec-42ad-b5a9-4922b899aebe

https://www.globenewswire.com/NewsRoom/AttachmentNg/28c9d533-c586-463b-97fd-5d7decdc9a7a

Palantir Technologies (PLTR 0.39%) and CoreWeave (CRWV 5.75%) have been among the most-watched stocks on the planet over the past year. They both have soared into the artificial intelligence (AI) space, proving their ability to play a key role here -- and that has won over both customers and investors.

Palantir's earnings have roared higher, and CoreWeave has seen revenue climb in the triple digits. And both companies have spoken of unstoppable demand. Palantir's stock has advanced more than 500% over the past five years, and CoreWeave's has climbed more than 80% since its initial public offering about a year ago.

But both companies have faced some headwinds along the way. Investors have worried about Palantir's high valuation and about CoreWeave's reliance on debt to grow its business. Still, Wall Street expects both stocks to advance over the coming 12 months -- but which is the better buy? Let's find out.

Image source: Getty Images.

The case for Palantir Palantir has been around for more than 20 years, but the company truly saw earnings take off in recent years. This is thanks to its role in the AI revolution. Palantir sells software that helps customers gather and analyze their data -- then use it to solve problems or improve their operations.

One particular Palantir platform, which integrates the power of large language models, has been highly popular in recent quarters. This is the Artificial Intelligence Platform (AIP), and it's helped the company's commercial business take off. In its earlier days, Palantir relied on government contracts for growth; today, government and commercial businesses are both major contributors to revenue. And Palantir also has demonstrated its strength in balancing revenue growth with profitability.

Today's Change

(

-0.39

%) $

-0.60

Current Price

$

152.59

As mentioned above, the one thing that's held some investors back is Palantir's sky-high valuation. Though after recent declines it's much lower than it was months ago, it remains hefty.

PLTR PE Ratio (Forward) data by YCharts

The case for CoreWeave CoreWeave offers AI customers access to something in high demand these days: capacity for AI workloads. The company has invested in a fleet of Nvidia graphics processing units (GPUs), the AI chips that drive major tasks such as training and inference, and offers them for rent. Customers can rent by the hour, offering them great flexibility -- they can go to CoreWeave for quick or long-term projects.

All of this has driven explosive growth quarter after quarter, and CoreWeave recently said that it's been the fastest cloud to reach $5 billion in annual revenue. The company now must invest to keep up with demand, including the $66 billion in contracted backlog.

Today's Change

(

-5.75

%) $

-4.57

Current Price

$

74.93

And this is where we get to the point that's weighed on the minds of some investors. CoreWeave, which already is highly leveraged, plans to increase spending. In fact, it will double capex from last year's level to $30 billion in 2026. This is to address the backlog, so the investment is leading to revenue growth, but investors still worry about the path to profitability as the company's losses have widened.

Which stock should you choose? Wall Street has more buy recommendations than sell recommendations for both stocks and expects them to climb in the months ahead. The average price forecast calls for a 27% increase for Palantir and a 67% gain for CoreWeave. So, according to Wall Street, CoreWeave may be the better buy right now.

That said, before making any moves, it's important to consider your investment strategy and feelings about risk. If you're a cautious investor, for example, these stocks probably aren't the best investments for you right now -- due to the negative points I've mentioned above. If you don't mind some risk, you might opt for Palantir -- in spite of the high valuation, the company is profitable and has demonstrated growth over time.

But if you're an aggressive investor who can accept the risk of investing in a highly leveraged company, you might follow Wall Street and bet on CoreWeave. Demand for compute could supercharge the stock in the months to come.

Nightingale Health Oyj (NGHLF) Q2 2026 Earnings Call March 5, 2026 7:00 AM EST

Company Participants

Teemu Suna - Founder, Interim CFO, CEO & Director
Janna Ranta - Chief Operating Officer

Conference Call Participants

Sami Sarkamies - Danske Bank A/S, Research Division

Presentation

Teemu Suna
Founder, Interim CFO, CEO & Director

Good afternoon and welcome to the half year results webcast of Nightingale Health. Today, we have the following agenda. I will talk first about Nightingale Health in brief, summarizing the technology and our business. Then we go to the business target of the current fiscal year. Then we will have a business update of the first half. And then we will go to financial review. And then finally, we have Q&A.

My name is Teemu Suna. I'm CEO and Founder of Nightingale Health and also Interim CFO. Let's start. So Nightingale Health, our mission is to build better health care for everyone. Company is founded 2013, headquartered here in Helsinki. But we are a global company. We have laboratories in United States, United Kingdom, Japan, Singapore and of course, here in Finland. We serve customers in B2B and B2G segments. And the focus is preventative health care and medical research.

So what Nightingale Health is all about? We -- our technology is building a global standard that will enable AI-powered preventative health care. The problem in health care at the moment is that there is no globally standardized clinical great way to measure health trajectories and intervention impact. So now because we cannot measure health and the health trajectories. The health care system is very reactive. So health care system is basically waiting people to get sick and then tries to do something about it.

And the reason why it is like this is that we are missing a

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fermi Inc. ("Fermi" or "the Company") (NASDAQ: FRMI) for violations of the federal securities laws.

Investors who purchased the Company's securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's October 2025 initial public offering ("IPO") and/or between October 1, 2025, and December 11, 2025, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 6, 2026. 

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Fermi overstated demand from tenants for the Project Matador campus. The Company misled investors about the extent to which it relied on a funding commitment from a single tenant to finance the construction of Project Matador. The Company suffered from a significant risk of funding commitment termination from this single tenant. Based on these facts, the Company's public statements were false and materially misleading throughout the IPO period. When the market learned the truth about Fermi, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CoreWeave, Inc. ("CoreWeave" or "the Company") (NASDAQ: CRWV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 28, 2025, and December 15, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before March 13, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. CoreWeave falsely claimed that it could meet customer demand while also downplaying the risk of relying on a single third-party vendor for data centers. The Company's failed acquisition of Core Scientific, delays in bringing data centers online, and media reporting revealed the truth about its operations. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about CoreWeave, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm